1Sarradall J. Drug utilization studies sources and methods[ M]. In:Hartzma Ac, ed. Pharmacoenidemiology. Cincinnaro: Harvey Whitney Book Company. 1992. 103-119.
2Grif K, Manfred P D, Pfaller K, et al. In vitro activity of fosfomycin in combination with various antistaphyloccal substances [J]. J Antimicrob Chemother , 2001,48: 209.
3Utsui Y, Ohya S, Magaribuchi T, et al. Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus [J]. Antimicrob Agents Chemother, 1986,30(6):917.
6Nabin K, Shrestha J, Tomford W. Fosfomycin: A review [J]. Infect Dis Clin Prac ,2001,10(5 ) :255.
7Del V O, Trincado P, Martin M T, et al. The prevalence of methicillin-resistant Staphylococcus aureus phagotype 95in the Hospitals vall d' Hebron of Barcelona [J]. Enferm Infecc Microbiol Clin,1999,17(10):498.
8Yoshida R, Kuwahara-Arai K, Baba T, et al. Physiological and molecular analysis of a mecA-negative Staphylococcus aureus clinical strain that expresses heterogeneous methicillin resistance [J]. J Antimicrob Chemoth, 2003,51:247.
9Robert D S, John S B. Evolving antimicrobial chemotherapy for Staphylococcus aureus infections [J]. Crit care Med,2001,29(Suppl 4) :N92.
10Watanabe T, Kanno M, Sobu K, et al. In vitro studies on the combined effects of arbekacin and fosfomycin on methicillin-resistant Staphylococcus aureus [ J ]. J Antibiot, 1995,48 (2): 284.
